Across TCGA pan-cancer cohorts, GLO1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated GLO1 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GLO1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLO1 expression acts as an unfavorable survival marker.
LUSC and ESCA are the cancer types where GLO1 Mutation most reproducibly stratifies survival.